Investment Objective and Approach

The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies. The fund predominantly seeks to generate consistent returns from investing in companies benefiting directly and indirectly from the pharma and allied sectors in India. It invests in equities across the market capitalisation spectrum.

It is an open-ended equity fund that predominantly invests in equity and equity-related securities in large-cap, mid-cap, and small-cap companies. Nippon India Pharma Fund Direct Plan Growth Plan Growth is a sectoral fund that focuses on investing in direct and associated companies in the pharmaceutical sector.

The fund follows a concentrated investment approach with asset allocation for Nippon India Pharma Fund is as follows: Cash & Equivalents | 0.53% This data is as on 30th July 2025.

Fund Managers

Sailesh Raj Bhan is the Current Fund Manager of Nippon India Pharma Fund Direct Growth fund. Sailesh has Over 10 years experience in Equity Securities research and analysis. he is in Reliance Capital Asset Management Limited as managing various Schemes of Reliance Mutual Fund From 2003 to till date

Mr. Bhan currently works at Reliance Nippon Life Asset Management Limited in Fund Management, where he manages the AMC's flagship diversified equity schemes. Sailesh also manages the largest pharma sector fund in India, as well as the Reliance Consumption Fund – a broad-based consumption thematic product since 2004. He also advises on international mandates for certain strategies in the past few years.

About the Fund House (AMC)

Nippon India Mutual Fund was launched as a joint venture between Japan's Nippon Life Insurance Company and India's Reliance Capital way back in 1996. Nippon purchased the stake of Reliance in October 2019 and the fund house has been renamed as Nippon India Mutual Fund.

It has Nippon Life Insurance Company as the sponsor and Reliance Capital Trustee Co. Ltd. as the trustee. Nippon India Mutual Fund is one of India's leading mutual funds, with Average Assets Under Management (AAUM) of Rs 2,79,431 Crores​​. NIMF has been established as a trust under the Indian Trusts Act, 1882 with Nippon Life Insurance Company as its Sponsor and Nippon Life India Trustee Ltd as its Trustee.

Key financials as of August 2025:

- AUM ₹617,875.25 Cr. No. of Schemes 329

- AddressNippon Life India Asset Management Limited, 4th Floor, Tower A, Peninsula Business Park, Mumbai, Maharashtra, 400 013

Should I Invest in Nippon India Pharma Fund?

This sectoral fund comes with specific considerations for different investor profiles:

Suitable for:

The Nippon India Pharma Fund Direct Plan is suitable for investors with advanced knowledge of macroeconomic trends who are ready to take higher risks for higher returns. If the aim is to generate long-term appreciation from selective exposure to high-risk concentrated portfolios, you may consider investing in Nippon India Pharma Fund Direct.

Risk Considerations:

The fund invests in a concentrated portfolio, which increases the investment risk. Investors investing in the fund may experience losses even when the overall market is positive. The Nippon India Pharma Fund Direct Growth is rated Very High risk.

Investment Horizon:

The recommended period to generate returns from the fund is 2-3 years. However, Warning: Do not invest in this, or any other pharma sector fund, if you need to redeem your investment in less than seven years.

Alternative Considerations:

We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in flexi-cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains. But if you do invest, you must do so only through the SIP route.

FAQs

What is today's NAV of Nippon India Pharma Fund?

The latest NAV varies daily. The latest NAV decalared is ₹572.241 as on 06 Aug 2025 at 12:14 am. Check the current NAV on Allvest platform or the official fund website.

What is the AUM of Nippon India Pharma Fund?

The AUM (i.e. assets under management) of Nippon India Pharma Fund is ₹8569.15 Cr as of 30th July 2025.

What is the expense ratio of Nippon India Pharma Fund?

The expense ratio of Nippon India Pharma Fund Plan is 0.89 as of 30th July 2025.

What are the returns of Nippon India Pharma Fund since inception?

Nippon India Pharma Fund Direct-Growth scheme return performance in last 1 year is 5.77%, in last 3 years is 90.80% and 725.32% since scheme launch.

What is the minimum SIP amount to invest in Nippon India Pharma Fund?

The min. SIP amount to invest in this scheme is ₹100. Some platforms may have different minimums.

How do I invest in Nippon India Pharma Fund?

You can invest through Allvest platform, fund house website, or authorized distributors. Complete your KYC and choose between SIP or lump sum investment options.

How to start a SIP in Nippon India Pharma Fund?

Register on Allvest platform, complete KYC, select the fund, choose SIP option, set investment amount (minimum ₹100) and frequency. Set up auto-debit mandate for seamless investments.

How do I automate an SIP in Nippon India Pharma Fund?

Set up a bank mandate through Allvest platform which automatically debits the SIP amount from your bank account on the chosen date each month.

How can I withdraw/redeem my investment in Nippon India Pharma Fund?

Log into your Allvest account, select the fund, choose redemption option, specify units/amount to redeem. Exit load of 1% if redeemed within 1 month. Funds typically credit within 3-4 working days.